Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2017

View Archived Issues

Ono reviews developments of second quarter of fiscal 2017

Sanofi presents key product and pipeline events of third quarter 2017

FDA clears Sarepta Therapeutics' IND for DMD candidate

OncoResponse completes acquisition of Paganini Biopharma

NX-AS-401 enhances the antibiotic effect of tobramycin in vitro and in vivo

FDA grants RMAT designation to Cellvation's CEVA-101

Invirsa closes seed financing to develop INV-102

Synlogic's SYNB-1020 demonstrates safety and tolerability in phase I study

CRISPR/Cas technology used to target HPV oncoprotein E6 for cervical cancer

Long-lasting enhancement of cognitive capabilities using AAV vector expressing the Klotho gene

Nightstar Therapeutics licenses gene therapy for Stargardt disease

Sosei gains Japanese license to HTL-0018318 for dementia with Lewy bodies under Allergan partnership

Torrent Pharmaceuticals discloses novel PI3K inhibitors

Boehringer Ingelheim initiates first-in-human study of BI-894416

ApoGlyx divulges new AQP9 inhibitors

Millendo Therapeutics reports topline phase II results on ATR-101, discontinues MLE-4901

AstraZeneca conducts phase I trial of MEDI-1341

Novartis reports topline results from MONALEESA-7 study of Kisqali

Viiv conducts first-in-human study of maturation inhibitor GSK-3640254

Bristol-Myers Squibb identifies Nav1.7 channel blockers

Synermore compares safety and pharmacokinetics of SYN-060 to Humira

Samumed presents DYRK1A, GSK-3beta and IL-6 production inhibitors

Trial data reported for dabrafenib/trametinib/navitoclax in BRAF-mutant solid tumor patients

Rexahn Pharmaceuticals doses first patient in phase IIa study of RX-3117 plus Abraxane

HSP 90 inhibitors presented by Duke University

Novita initiates phase I study of NP-G2-044 in advanced or metastatic solid tumors

FDA approves Prevymis for CMV prevention in adult HSCT recipients

Neurimmune collaborates with Ono on discovery of antibodies for neurodegenerative diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...